文献速递产科母胎医学

硝苯地平与阿托西班对围产期脑损伤的影响:APOSTEL-III试验的二次分析

Effect of nifedipine and atosiban on perinatal brain injury: secondary analysis of the APOSTEL-III trial.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-01-01

该研究为APOSTEL-III随机临床试验的二次分析,纳入在两个主要参与中心于≤32周分娩的孕妇所生117名新生儿,比较产前使用硝苯地平或阿托西班对新生儿脑损伤的影响。结果显示两组总体脑损伤、轻度及重度脑损伤、脑室内出血发生率均无显著差异,但该二次分析对脑损伤的检验效能不足。

要点

  • 在≤32周分娩的新生儿中,产前使用硝苯地平或阿托西班后脑损伤总体发生率分别为43.1%和56.1%,无显著差异。
  • 重度脑损伤在硝苯地平组为9.8%、阿托西班组为7.6%,两组无显著差异。
  • 脑室内出血(≥I级)是最常见的超声异常,两组发生率分别为35.3%和37.9%,无显著差异。

核心结论

  • 在<32周早产儿中,产前使用硝苯地平或阿托西班后脑损伤患病率均较高,但两组间总体脑损伤无显著差异。
  • 由于该研究为APOSTEL-III试验的二次分析,对脑损伤结局的检验效能不足。

研究设计与样本

  • APOSTEL-III随机临床试验的二次分析,该试验将25至34周先兆早产的孕妇随机分配至硝苯地平组或阿托西班组。
  • 本二次分析纳入两个主要参与中心中在≤32周分娩的孕妇所生新生儿,共117名新生儿(来自102名孕妇),其中51名暴露于硝苯地平、66名暴露于阿托西班。
  • 主要结局为新生儿脑损伤,定义为超声检查发现异常,并分为轻度和重度;分析新生儿重症监护及中等护理期间所有新生儿超声检查。

主要发现

  • 总体脑损伤在硝苯地平组为22/51(43.1%),阿托西班组为37/66(56.1%),OR 0.60(95% CI 0.29-1.24)。
  • 轻度脑损伤在硝苯地平组为33.3%,阿托西班组为48.5%,OR 0.53(95% CI 0.25-1.13)。
  • 重度脑损伤在硝苯地平组为9.8%,阿托西班组为7.6%,OR 1.33(95% CI 0.36-4.85)。
  • 脑室内出血(≥I级)在硝苯地平组为18/51(35.3%),阿托西班组为25/66(37.9%),OR 0.90(95% CI 0.42-1.91)。
  • 校正母亲年龄和随机化时孕周的敏感性分析显示,两组脑损伤发生无统计学差异(OR 0.58;95% CI 0.27-1.27)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该研究为APOSTEL-III试验的二次分析,对脑损伤结局的检验效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Brain injury in neonates born prematurely is associated strongly with poor neurodevelopmental outcome. The aim of this study was to evaluate whether tocolysis with nifedipine or atosiban in women with threatened preterm birth can reduce the incidence of overall brain injury in neonates born prematurely. METHODS: This was a secondary analysis of the APOSTEL-III trial (Dutch Clinical Trial Registry, no. NTR2947), a randomized clinical trial in which women with threatened preterm labor between 25 and 34 weeks of gestation were allocated to treatment with nifedipine or atosiban. In this secondary analysis, women delivered at ≤ 32 weeks of gestational age in the two main contributing centers were included. Primary outcome was the presence of neonatal brain injury, which was defined as presence of abnormalities on ultrasound investigation and classified into mild and severe. To evaluate type and severity of brain injury, all neonatal ultrasounds performed during neonatal intensive and medium care admission were analyzed. To test the robustness of our results, a sensitivity analysis was performed assessing differences in baseline or known risk factors for brain injury. RESULTS: A total of 117 neonates (from 102 women) were studied, of which 51 had been exposed to nifedipine and 66 to atosiban. Brain injury was observed in 22 (43.1%) neonates in the nifedipine group compared with 37 (56.1%) in the atosiban group (OR, 0.60; 95% CI, 0.29-1.24). Presence of mild brain injury was comparable between the nifedipine (33.3%) and atosiban (48.5%) groups (OR, 0.53; 95% CI, 0.25-1.13). Severe brain injury was also comparable between the groups, observed in 9.8% of neonates in the nifedipine vs 7.6% of those in the atosiban group (OR, 1.33; 95% CI, 0.36-4.85). Intraventricular hemorrhage (≥ Grade I) was the most frequently seen ultrasound abnormality, observed in 18 (35.3%) neonates in the nifedipine group vs 25 (37.9%) in the atosiban group (OR, 0.90; 95% CI, 0.42-1.91). The sensitivity analysis, with adjustment for maternal age and gestational age at randomization, showed no statistical difference between the groups for presence of brain injury (OR, 0.58; 95% CI, 0.27-1.27). CONCLUSION: In children born before 32 weeks of gestation after the use of tocolytics, the prevalence of brain injury was high. No significant differences were found with respect to overall brain injury between neonates exposed to nifedipine and those exposed to atosiban. However, as this study was a secondary analysis of the APOSTEL III trial, it was underpowered for brain injury. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Nijman TAJ, Goedhart MM, Naaktgeboren CN, et al. Effect of nifedipine and atosiban on perinatal brain injury: secondary analysis of the APOSTEL-III trial. Ultrasound Obstet Gynecol. 2018. PMID: 28452086. doi:10.1002/uog.17512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。